Anavex Life Sciences (AVXL) Dividend History

Company News

• ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Long-Term Investors to Contact the Firm

  Kaskela Law LLC is investigating potential breach of fiduciary duty claims against Anavex Life Sciences Corp. (AVXL) regarding the company's misleading statements about its Rett syndrome drug blarcamesine and the failure of its clinical trial.

  GlobeNewswire Inc.
• Anavex Life Sciences: Short-Squeeze Target Gains Traction

  Anavex Life Sciences (AVXL) is a short-squeeze candidate due to rising share prices, institutional and analyst support, and high short interest. The company's Alzheimer's treatment, blarcamesine, has shown promising results and is expected to receive EU approval in 2025, potentially generating significant revenue.

  Investing.com
• US Stocks To Open Higher As Wall Street Expects 'Santa Rally' In Shortened Trading Week: MicroStrategy, Palantir, Qualcomm Among Stocks In Focus

  US stock futures are expected to open higher as Wall Street anticipates a 'Santa Rally' in the shortened trading week. Key stocks in focus include MicroStrategy, Palantir, and Qualcomm.

  Benzinga

  Featured Companies: BNRG LAES MSTR PLTR QCOM QQQ SPY
• Anavex Life Sciences (AVXL) Upgraded to Buy: What Does It Mean for the Stock?

  Anavex Life Sciences (AVXL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  Zacks Investment Research
• Wall Street Thinks This Small-Cap Stock Can Quadruple in Value

  The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside.

  The Motley Fool